Antibodies News and Research

RSS

Sustained and effective response to Janssen COVID-19 vaccine Is enhanced by delayed booster

A new study adds to the data on the optimum interval between the first and second doses of the adenovirus vectored COVID-19 vaccine.

30 Aug 2021

Study reveals how SARS-CoV-2 variants of concern modulate receptor and antibody binding

In a trailblazing engineering effort, Canadian and US researchers indicate that the emergence of novel variants of SARS-CoV-2 stems from the mutations of spike glycoprotein that confer either increased affinity for the host cell receptor or increased antibody evasion.

30 Aug 2021

CoronaVac elicits lower antibody response than natural SARS-CoV-2 infection, study suggests

A recent study from Thailand highlights a rather low degree of neutralization-afforded protection mounted by the inactivated whole-virus CoronaVac vaccine compared to natural infection with SARS-CoV-2 – the virus that causes COVID-19.

30 Aug 2021

New study maps the evolution of the SARS-CoV-2 delta and delta plus variants

The SARS-CoV-2 delta variant bears the D164G mutation, which is known to enhance viral fitness. However, a number of additional mutations are known to be common to the delta and delta plus lineages, at least 25 as identified in a study recently published in the Journal of Autoimmunity, mainly located on the spike protein of the virus.

30 Aug 2021

Next-gen COVID vaccine to make persistent neutralizing antibodies

Presently, there is a need to develop improved versions of COVID-19 vaccines that are effective against the SARS-CoV-2 variants of concern (VOC) and can confer long-term protection. Considering the need of the hour, scientists from the University of Sydney in Australia have generated a new COVID-19 vaccine CoVac-II and evaluated its effect against COVID-19 strains. The findings from this study are published on the bioRxiv* preprint server while awaiting peer review.

30 Aug 2021

Can molecular mimicry impact fertility in female COVID-19 patients?

There exists a possibility that COVID-19 can also affect the reproductive function in the body, which can lead to infertility in infected patients. A study published in the American Journal of Reproductive Immunology explored the impact of SARS-CoV-2 infection on reproductive functions and fertility.

30 Aug 2021

Northwestern researchers continue investigation on all aspects of COVID-19 pandemic

Northwestern Medicine scientists continue to investigate all aspects of the COVID-19 pandemic: from molecular mechanisms of infection, to child hospitalization and single-dose vaccine response.

28 Aug 2021

MS patients on anti-CD20 therapy have robust T cell responses to SARS-CoV-2 vaccination

Scientists have observed that MS patients exhibit a robust T cell response despite a reduced humoral response to COVID-19 vaccines. Read more here.

27 Aug 2021

'Humanized' mouse model beats current approaches for finding the best organ donor

A "humanized" mouse model equipped with the immune system of a patient who needs an organ transplant beats current measures for identifying the best potential living donor, scientists report.

27 Aug 2021

ACTG announces positive data for monoclonal antibody combination therapy from the ACTIV-2 study

The AIDS Clinical Trials Group, the largest global HIV research network, which has expanded its focus to include evaluating outpatient treatment for COVID-19, today announced positive data for the monoclonal antibody combination therapy BRII-196/BRII-198 from the ACTIV-2 study of Outpatient Monoclonal Antibodies and Other Therapies.

27 Aug 2021

Adding berzosertib to standard treatment for metastatic urothelial cancer does not extend patient survival

A Phase 2 trial led by City of Hope, a world-renowned research and treatment center for cancer and diabetes, suggests that adding the novel ataxia telangiectasia and Rad3-related (ATR) inhibitor drug berzosertib to standard-of-care chemotherapy for patients with metastatic urothelial cancer does not extend progression-free survival.

27 Aug 2021

Study: 31% of Americans had been infected with SARS-CoV-2 by the end of 2020

A new study published in the journal Nature estimates that 103 million Americans, or 31 percent of the U.S. population, had been infected with SARS-CoV-2 by the end of 2020.

27 Aug 2021

Cytokine APRIL plays a protective role against formation of atherosclerotic plaques

Heart attacks and strokes are the main causes of death and loss of productive years globally. These clinical complications are caused by atherosclerosis, which is a chronic disease that leads to the accumulation of LDL cholesterol and immune cells in the inner layer of arteries and thereby resulting in the build-up of atherosclerotic plaques.

26 Aug 2021

The influence of COVID-19 on platelet activation and aggregation

In a paper recently uploaded to the bioRxiv* preprint server, humanized ACE2 mice are infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and platelets are subsequently isolated from the blood for quantitative proteomic analysis.

26 Aug 2021

Scientists assess SARS-CoV-2 mutants in ferret hosts

In a paper recently uploaded to the preprint server bioRxiv* by the cause of SARS-CoV-2 mutations observed in mink and ferrets is investigated, and the danger posed by such mutations to humans assessed.

26 Aug 2021

Aptamer Group and Bio-Works Technologies partner to enable improved solutions for gene therapy manufacturing

Aptamer Group Ltd and Bio-Works Technologies AB today announce that they have entered into an agreement to co-develop a new affinity resin.

From Aptamer Group 26 Aug 2021

Large UK study examines impact of Delta variant on viral burden and vaccine effectiveness

Now, a new study published on the medRxiv* preprint server focused on determining the effectiveness of the BNT162b2, ChAdOx1, and mRNA-1273 vaccines by conducting SARS-CoV-2 PCR-positive tests.

26 Aug 2021

Two mRNA vaccines are effective even without post-shot symptoms or prior SARS-CoV-2 infection

Vaccination with the two messenger RNA (mRNA) vaccines for SARS-CoV-2, the virus that causes COVID-19, yields a robust antibody response, even if a person did not develop significant symptoms following vaccination or did not have a prior SARS-CoV-2 infection.

26 Aug 2021

Higher SARS-CoV-2 Delta variant transmission among K-12 schoolchildren can be reduced by interventions, says study

A new study reports the results of a model framed to explore the transmission of the delta variant among schoolchildren and the most effective intervention methods to minimize such spread.

25 Aug 2021

Analysis of antibody titer decay following vaccination or SARS-CoV-2 infection

A new study focused on the decrease in antibody titers following two doses of BNT162b2 vaccine or SARS-CoV-2 natural infection in Israel.

25 Aug 2021

Antibodies News and Research

Sustained and effective response to Janssen COVID-19 vaccine Is enhanced by delayed booster

Study reveals how SARS-CoV-2 variants of concern modulate receptor and antibody binding

CoronaVac elicits lower antibody response than natural SARS-CoV-2 infection, study suggests

New study maps the evolution of the SARS-CoV-2 delta and delta plus variants

Next-gen COVID vaccine to make persistent neutralizing antibodies

Can molecular mimicry impact fertility in female COVID-19 patients?

Northwestern researchers continue investigation on all aspects of COVID-19 pandemic

MS patients on anti-CD20 therapy have robust T cell responses to SARS-CoV-2 vaccination

'Humanized' mouse model beats current approaches for finding the best organ donor

ACTG announces positive data for monoclonal antibody combination therapy from the ACTIV-2 study

Adding berzosertib to standard treatment for metastatic urothelial cancer does not extend patient survival

Study: 31% of Americans had been infected with SARS-CoV-2 by the end of 2020

Cytokine APRIL plays a protective role against formation of atherosclerotic plaques

The influence of COVID-19 on platelet activation and aggregation

Scientists assess SARS-CoV-2 mutants in ferret hosts

Aptamer Group and Bio-Works Technologies partner to enable improved solutions for gene therapy manufacturing

Large UK study examines impact of Delta variant on viral burden and vaccine effectiveness

Two mRNA vaccines are effective even without post-shot symptoms or prior SARS-CoV-2 infection

Higher SARS-CoV-2 Delta variant transmission among K-12 schoolchildren can be reduced by interventions, says study

Analysis of antibody titer decay following vaccination or SARS-CoV-2 infection

How to make hybridoma-based antibody discovery more efficient eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo